cardio exam 3

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/171

encourage image

There's no tags or description

Looks like no tags are added yet.

172 Terms

1
New cards

what factors do warfarin inhibit

-VII

-X

-IX

-II

2
New cards

what factors do rivaroxaban inhibit

Xa

3
New cards

what factors do apixaban inhibit

Xa

4
New cards

what factors do edoxaban inhibit

Xa

5
New cards

what factors do fondaparinux inhibit

Xa

6
New cards

what factors do enoxaparin inhibit

Xa

7
New cards

what factors do delteparin inhibit

Xa

8
New cards

what factors do bivalirubin inhibit

IIa

9
New cards

what factors do argatroban inhibit

IIa

10
New cards

what factors do dabigatran inhibit

IIa

11
New cards

derivative of heparin

fondaparinux

12
New cards

examples of low molecular weight heparin (LMWH)

Enoxaparin

Dalteparin

13
New cards

direct thrombin inhibitors

-Dabigatran

-bivalirubin

-argatroban

14
New cards

what drug is a family of sulfated glycosaminoglycans

heparin

15
New cards

what drug is extracted from beef lung or hog intestine

heparin

16
New cards

what drugs are isolated from standard heparin by gel filtration chromatography

low molecular weight heparins

17
New cards

heparin MOA

inhibits coagulation by activating antithrombin, antithrombin inhibits thrombin and other serine proteases by binding to the active serine site

18
New cards

LMWHs increase the action of ______ on factor Xa but not its action on thrombin

antithrombin

19
New cards

clinical use of heparin

-venous thrombosis, PE

-unstable angina or MI

-during or after coronary balloon angioplasty or stent placement

-disseminated intravascular coagulation

20
New cards

what is the drug of choice for anticoagulation during pregnancy

heparin

21
New cards

adverse effect of heparin

-bleeding

-heparin induced thrombocytopenia

22
New cards

antidote for heparin

protamine sulfate

23
New cards

adverse effects of protamine

-anaphylaxis

-hypotension

-pulmonary vasoconstriction

24
New cards

MOA of heparin induced thrombocytopenia (HIT)

development of an antibody against complexes of heparin with platelet factor 4 which activate platelet and thrombin generation

25
New cards

treatment of HIT

-discontinue heparin

-treat with bivalirudin, argatroban

26
New cards

MOA of LMWH

increase the inhibitory action of antithrombin on factor Xa but not its action on thrombin

27
New cards

clinical use of LMWH

-DVT

-thromboembolism

-unstable angina

-hip replacement

-pregnant

28
New cards

MOA of fondaparinux

indirect factor Xa inhibitor

29
New cards

clinical use of fondaparinux

- thromboprophylaxis

- PE

- DVT

30
New cards

adverse effects of fondaparinux

bleeding, thrombocytopenia

31
New cards

MOA of bivalirudin

-recombinant derivative of hirudin

-binds irreversibly both to the fibrin binding and catalytic sites on thrombin, inhibiting thrombin activity

32
New cards

clinical use of bivalirudin

alternative to heparin in patients undergoing coronary angioplasty with HIT history

33
New cards

adverse effect of bivalirudin

bleeding

34
New cards

MOA of argatroban

synthetic direct thrombin inhibitor that binds irreversibly to the catalytic site of thrombin

35
New cards

Clinical use of Argatroban

alternative to bivalirubin for prophylaxis or treatment of patients with or at risk of developing HIT

36
New cards

adverse effects of argatroban

bleeding

37
New cards

what inhibits vitamin K reductase leading to anticoagulation effects

warfarin

38
New cards

what factor has the longest half life

Factor II

39
New cards

clinical use of warfarin

-DVT or PE following heparin

-prevent stroke or systemic embolism

40
New cards

adverse effects of warfarin

-bleeding

-skin necrosis

41
New cards

treatment of bleeding with warfarin

-test INR

-withhold or reduce warfarin

-administration of vitamin K

-infusion of fresh plasma or coagulation factor concentrates

42
New cards

CYP2C9 inducers that interact with warfarin

barbiturates, carbamazepine, rifampin, phenytoin

43
New cards

CYP2C9 inhibitors that interact with warfarin

amiodarone, azole antifungals, disulfiram, metronidazole, fluoxetine

44
New cards

interactions with warfarin

-vitamin K availability

-low coagulation factors

-alcohol

-aging

45
New cards

MOA of rivaroxaban

inhibits factor Xa, results in reduced thrombin generation, suppresses platelet aggregation and fibrin formation

46
New cards

interaction with rivaroxaban

ketoconazole, itraconazole, ritonavir, and clarithromycin

47
New cards

clinical use of rivaroxaban

-DVT

-PE

-prevention of thrombosis in Afib, knee replacement surgery

48
New cards

MOA of dabigatran

converted by plasma esterase to active dabigatran, reversible direct thrombin inhibitor

49
New cards

clinical use of dabigatran

-DVT

-PE

-prevent stroke or systemic embolism

50
New cards

adverse effects of dabigatran

bleeding and GI upset

51
New cards

antidote of dabigatran

Idarucizumab

52
New cards

Cox1 inhibitor

aspirin

53
New cards

P2Y12 inhibitors

-Clopidogrel

-Prasugrel

-Ticagrelor

-cangrelor

54
New cards

fibrinogen receptor (GPIIb/IIIa) antagonists

-abciximab

-eptifibatide

-tirofiban

55
New cards

MOA of aspirin

blockade of thromboxane production through irreversible blocking of cyclooxygenase

56
New cards

clinical use of aspirin

-prevent thrombosis that lead to MI, ischemic stroke, peripheral vascular thrombosis

-undergoing coronary artery intervention

-analgesic, antipyretic, treatment of rheumatoid disease

57
New cards

MOA of dipyridamole

Inhibits the uptake of adenosine into platelets and increases cAMP levels, which inhibits platelet aggregation

58
New cards

clinical use of dipyridamole

-used in combination with warfarin to decrease thrombosis in patients after artificial heart valve replacement

-used with aspirin for stroke prevention

-vasodilator

59
New cards

true or false: dipyridamole is typically given on its own

false

60
New cards

adverse reaction of dipyridamole

headache, palpitation

61
New cards

clopidogrel is activated into its active form by what

CYP2C19

62
New cards

MOA of clopidogrel

prodrug that requires activation by CYP2C19 in liver with slow onset action and slow offset action. Active clopidogrel irreversibly inhibits ADP P2Y12 receptor, blocking ADP-induced platelet aggregation.

63
New cards

clinical use of clopidogrel

-after angioplasty with aspirin

-recent stroke or MI, peripheral arterial disease, acute coronary syndrome

64
New cards

adverse effects of clopidogrel

-bleeding

-thrombotic thrombocytopenia purpura (TTP)

65
New cards

what is TTP treated with

plasma replacement and caplacizumab

66
New cards

difference of prasugrel from clopidogrel

-more rapid onset of action

-greater inhibition of ADP induced platelet aggregation

-higher risk of bleeding

67
New cards

MOA of ticagrelor

An oral, reversible, non-thienopyridine antagonist of the P2Y12 receptor that provides more rapid and predictable levels of antiplatelet therapy

68
New cards

clinical use of ticagrelor

-acute coronary syndrome

-patients undergoing coronary intervention

69
New cards

MOA of cangrelor

reversible inhibitor of P2Y12

70
New cards

Clinical use of cangrelor

patients undergoing percutaneous coronary intervention

71
New cards

MOA of aciximab

Fab fragment of a humanized monoclonal antibody against the GP IIb/IIIa receptor complex and inhibits platelet aggregation

72
New cards

clinical use of aciximab

patients undergoing percutaneous coronary intervention and acute coronary syndrome

73
New cards

adverse effects of aciximab

bleeding and thrombocytopenia

74
New cards

MOA of eptifibatide

cyclic peptide inhibitor of the fibrinogen binding site on GPIIb/IIIa

75
New cards

MOA of tirofiban

small-molecule inhibitor of GPIIb/IIIa

76
New cards

fibrinolytics

-Alteplase

-Tenecteplase

77
New cards

MOA of alteplase

recombinant tissue plasminogen activator (t-PA), initiates local fibrinolysis by binging to fibrin in a thrombus and converts entrapped plasminogen to plasmi

78
New cards

indications of alteplase

-Acute coronary arterial thrombosis

-Acute pulmonary thromboembolism

-Acute ischemic stroke

-Central venous catheter clearance

79
New cards

half life of alteplase

5 minutes

80
New cards

adverse effects of alteplase

- bleeding

- arrhythmias during coronary arterial thrombosis

81
New cards

MOA of tenecteplase

modified form of t-PA, binds to the fibrin component of the thrombus and selectively converts thrombus-bound plasminogen to plasmin, which degrades the fibrin matrix of the thrombus

82
New cards

indication of tenecteplase

acute MI

83
New cards

the half life of tenecteplase is ____ compared to alteplasse

increased

84
New cards

adverse effects of tenecteplase

bleeding, arrhythmias

85
New cards

Anti-fibrinolytics

aminocaproic acid

tranexamic acid

86
New cards

MOA of aminocaproic acid

lysine analog that competes for lysine binding sites on plasminogen and plasmin, thus blocking the interaction of plasmin with fibrin

87
New cards

clinical use of aminocaproic acid

- fibrinolytic bleeding (post operative, hemorrhagic conditions)

- overdose of thrombolytic agents

88
New cards

side effects of aminocaproic acid

- myopathy, muscle necrosis

- intravascular thrombosis

- hypotension

- abdominal discomfort

-rhabdomylosis

89
New cards

what does mutations in LDL-receptor gene lead to

familial hypercholesterolemia

90
New cards

bile acid sequestrants

-cholestyramine

-colesevelam

-colestipol

91
New cards

LPL activator

niacin

92
New cards

HMG-CoA reductase inhibitors

-atorvastatin

-lovastatin

-pravastatin

-rosuvastatin

-simvastatin

93
New cards

Cholesterol absorption (NPC1L1) inhibitor

Ezetimibe

94
New cards

Fibric acid (PPAR agonist)

Fenofibrate

Gemfibrozil

95
New cards

PCSK9 inhibitors

-Alirocumab

-Evolocumab

-Inclisiran

-lerodalcibep

-enlicitide

96
New cards

MTTP inhibitor

Lomitapide

97
New cards

Omega-3 Fatty Acids

icospent ethyl

98
New cards

ANGPTL3 inhibitor

Evinacumab

99
New cards

ATP Citrate Lyase (ACL) Inhibitor

bempedoic acid

100
New cards

ApoC-III inhibitors

-plozasiran

-olezarsen